TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05767515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
Study: NCT04829292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive therapy and CBT
Description: In this open trial participants are first offered supportive therapy followed by CBT
Study: NCT05773846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: A long acting formulation of ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: A long acting formulation of ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: A long acting formulation of ropivacaine
Study: NCT06316830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine in a highly effective treatment for opioid use disorder (OUD). Buprenorphine dose guidelines for OUD treatment were determined by clinical trials conducted in populations with a history of heroin use. However, fentanyl is changing the calculation of treatment, and optimal buprenorphine dosing for people who use fentanyl is unknown.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine in a highly effective treatment for opioid use disorder (OUD). Buprenorphine dose guidelines for OUD treatment were determined by clinical trials conducted in populations with a history of heroin use. However, fentanyl is changing the calculation of treatment, and optimal buprenorphine dosing for people who use fentanyl is unknown.
Study: NCT04635449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Age-specific information booklet and targeted telephone call
Description: age-specific information, complemented by a follow-up targeted telephone call to reduce psychological sequelae in the child and their parents after PICU discharge.
Study: NCT04819945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GATT-Patch
Description: Use of GATT-Patch for minimal, mild or moderate bleeding sites in open liver surgery
Study: NCT05533671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medial patellofemoral reconstruction
Description: Surgery to correct dislocated (knocked out of place) knee cap. This surgery anchors the kneecap back into the correct position and supports the kneecap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative group
Description: Physical therapy by following a specific regimen.
Study: NCT06279741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotracheopulmonary Instillation, Suspension
Description: The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotracheopulmonary Instillation, Suspension
Description: The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotracheopulmonary Instillation, Suspension
Description: The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endotracheopulmonary Instillation, Suspension
Description: The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant.
Study: NCT04903210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide mononucleotide supplied as 400mg capsule
Description: NMN10000 WRIGHT LIFE® + lifestyle modification NMN10000 WRIGHT LIFE®: 800mg, qd, for two months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification
Description: Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
Study: NCT04852367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release
Study: NCT05330013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Subjects will be instructed to take dapagliflozin 10 mg once daily for 6 months (with or without food).

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: For subjects, depending on the subject's heart rate, base, mild, or apex short-axis slices will be acquired during the first pass of the contract (60 measurements).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: For subjects, depending on the subject's heart rate, base, mild, or apex short-axis slices will be acquired during the first pass of the contract (60 measurements).

Intervention type: DEVICE
Group type: OTHER
Intervention: CMR imaging
Description: Enrolled subjects will undergo stress vasodilator and rest perfusion CMR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMR imaging
Description: Enrolled subjects will undergo stress vasodilator and rest perfusion CMR
Study: NCT04836468

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tape application
Description: Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Tape application
Description: Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.
Study: NCT05312593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aftoral Oral Gel
Description: Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unidea Chlorhexidine mouthwash
Description: Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
Study: NCT05672251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05975723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND diet education
Description: An intensified education program following a localized modified MIND diet for 1 year, which recommends 11 brain healthy food groups (green leafy vegetables, dark red and yellow vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive/tea-seed oil and green tea) and limits intake of 4 unhealthy food groups (red meat and products, animal oil, pastries and sweets, and fried/fast food).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up and general advice
Description: Routine follow-up administered by trained staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine follow-up and general advice
Description: Routine follow-up administered by trained staff.
Study: NCT05605808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Aerobic exercise by using the treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes in weeks 2-12.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises
Description: Aerobic exercise by using the treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes in weeks 2-12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet protocol
Description: A specific diet for three months is designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet protocol
Description: A specific diet for three months is designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins.
Study: NCT05765422

Intervention type: OTHER
Group type: OTHER
Intervention: salivar and gum sampling
Description: Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum

Intervention type: OTHER
Group type: OTHER
Intervention: salivar and gum sampling
Description: Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum

Intervention type: OTHER
Group type: OTHER
Intervention: salivar and gum sampling
Description: Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum
Study: NCT04852367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: ThermoDox infusion
Study: NCT06000137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dezocine
Description: dezocine for patient-controlled analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dezocine
Description: dezocine for patient-controlled analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil injection
Description: sufentanil for patient-controlled analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: Flurbiprofen for patient-controlled analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: Flurbiprofen for patient-controlled analgesia
Study: NCT03962465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Pill
Description: Taken daily days 1-28 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Pill
Description: Taken daily days 1-28 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: By IV, given on days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: By IV, given on days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: By IV, given on days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: By IV, given on days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intrathecal, administered on day 1 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intrathecal, administered on day 1 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal, administered on days 8 and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal, administered on days 8 and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: By IV, given on day 4
Study: NCT05397730

Intervention type: DIAGNOSTIC_TEST
Intervention: Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)
Description: Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis

Intervention type: DIAGNOSTIC_TEST
Intervention: Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)
Description: Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
Study: NCT06313255

Intervention type: DRUG
Intervention: PegIFNα2b
Description: The patients receive PegIFNα2b therapy

Intervention type: DRUG
Intervention: PegIFNα2b+probiotics
Description: The patients receive both PegIFNα2b and probiotics therapy

Intervention type: DRUG
Intervention: Nucleoside analog
Description: The patients receive nucleoside analog therapy

Intervention type: DRUG
Intervention: Nucleoside analog+probiotics
Description: The patients receive both nucleoside analog and probiotics therapy
Study: NCT04325802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 50mg Naltrexone daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50mg Naltrexone daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (Mannitol) daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (Mannitol) daily
Study: NCT06390397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Produce prescription program
Description: Boxes of fresh fruit and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks. Participants will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care includes routine lab work collection and weight and diet counseling for overweight or obese children. Additionally, referrals placed to community resources for those identified with Social Determinants of Health(SDOH) needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care includes routine lab work collection and weight and diet counseling for overweight or obese children. Additionally, referrals placed to community resources for those identified with Social Determinants of Health(SDOH) needs.
Study: NCT05945784

Intervention type: OTHER
Intervention: Use of Rare Beauty makeup products
Description: Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.
Study: NCT05919576

Intervention type: DEVICE
Intervention: Near infrared imaging
Description: In the study, all volunteers are recorded with the itero Element 5D by activating the NIRI mode. The recording method does not involve ionizing radiation. 850 nm wavelength beams are used.
Study: NCT05986916

Intervention type: DIAGNOSTIC_TEST
Intervention: Liverscope® exam
Description: Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).

Intervention type: DIAGNOSTIC_TEST
Intervention: MR exam
Description: Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.

Intervention type: DIAGNOSTIC_TEST
Intervention: FibroScan® exam (optional)
Description: Participants may undergo a FibroScan® exam (optional) to evaluate liver fat and liver stiffness.

Intervention type: OTHER
Intervention: Blood draw
Description: Participants will undergo a blood draw (approximately 10 mL) for measurement of CBC, platelets, and complete metabolic panel with transaminases.

Intervention type: OTHER
Intervention: Body measurements
Description: Participants will have their height, weight, waist circumference, and hip circumference measured.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be asked to fill out questionnaires to collect information about their alcohol consumption, history of cigarette smoking, presence of diabetes, and history of liver disease and medications
Study: NCT06131255

Intervention type: DRUG
Intervention: Citalopram
Description: Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM
Study: NCT05559450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be bridged to conventional BUCY conditioning regimen.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy
Description: Control group will be given conventional BUCY conditioning regimen.
Study: NCT05732467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: visual function training software
Description: Experimental group: If there is a refractive problem, first correct the refraction, wear corrective glasses, and then use visual function training therapy software (model: SJ-JRS2021) for treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: occlusion therapy
Description: Control group: If there is a refractive problem, correct the refraction first, wear corrective glasses combined with occlusion therapy, and cover the fellow eye for 2 hours a day.

Intervention type: OTHER
Group type: OTHER
Intervention: corrective glasses
Description: corrective glasses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corrective glasses
Description: corrective glasses
Study: NCT05616286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-SOS for Refugees
Description: Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The Mindfulness-SOS for Refugees intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs.
Study: NCT05684536

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: liagsure device
Description: the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall, with dissection around ligament of berry and inferior thyroidal artery
Study: NCT04875286

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT04908423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin®
Description: To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
Study: NCT05219162

Intervention type: GENETIC
Group type: OTHER
Intervention: Gene Profile explore
Description: The tissue and blood sample for this genetic research will be obtained from the participants at baseline(disease progression after 1L Osimertinib). Paired tissue and whole blood sample should be collected per participant for genetics during the study.